Table 3.

Evaluation of dose of current oral domperidone exposure on risk of sudden cardiac death, nested case-control analysis: results of multivariable conditional logistic regression, reference group non-use of any study drug

Exposure category (categories are mutually exclusive)	SCD cases		Controls		Matched ORa	95 % CI	Adjusted ORb	95 % CI
	N	%	N	%
Current exposure to single oral domperidone alonec (estimated average daily dose) [mg/day]
<30	4	0.1	10	0.1	2.32	0.72–7.44	1.96	0.44–8.76
30	15	0.5	35	0.3	2.60	1.41–4.79	1.48	0.69–3.19
>30	8	0.2	5	0.0	9.07	2.95–27.88	3.20	0.59–17.34
No exposure to any study drug	802	24.8	4493	35.7	Reference		Reference

OR odds ratio, CI confidence interval, SCD sudden cardiac death, BMI body mass index, GP general practitioner, hERG human Ether-à-go-go-Related Gene

^aOR matched for age, sex, and practice

^bOR matched for age, sex, and practice and adjusted for the following covariates: history of serious ventricular arrhythmia, myocardial infarction, heart failure, valvular heart disease including valve replacement, cardiomyopathy, other arrhythmia or conduction disorder, epilepsy, depression, group 2 QTc-prolonging drugs, drugs that affect hERG, digoxin, diuretics, laxatives, β-blockers, BMI, alcohol use, smoking history, number of GP visits, and number of hospital admissions

^cOral exposure only; analysis excludes one case and one control with rectal exposure and one control for whom dose could not be determined